Related Experiment Video
Updated: Feb 5, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Tissue-targeted complement therapeutics
Stephen Tomlinson1, Joshua M Thurman2
1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Abstract:
Complement activation contributes to the pathogenesis of numerous inflammatory and autoimmune diseases. Therapeutic complement inhibitors have proven effective in several of these diseases and have now entered clinical use. Complement activation has multiple different biologic effects, however, and the currently available drugs can have undesirable side-effects, such as an increased risk of infection. Several different complement inhibitors have been developed that bind to target molecules, thereby concentrating the drug at a specific anatomic site. This approach appears to be both more effective than untargeted drugs and to have fewer side effects. In this article we review different targeting strategies that have been developed and the evidence supporting the use and benefits of targeted drugs.
Insights
Targeted complement inhibitors offer a promising therapeutic strategy for inflammatory and autoimmune diseases. This approach enhances drug efficacy and minimizes side effects compared to traditional treatments.
Area of Science:
- Immunology
- Pharmacology
- Autoimmune disease research
Background:
- Complement activation is implicated in various inflammatory and autoimmune diseases.
- Current complement inhibitors are effective but carry risks like infection.
- Developing targeted therapies is crucial for improved treatment outcomes.
Purpose of the Study:
- To review the development of targeted complement inhibitors.
- To evaluate the evidence supporting targeted drug strategies.
- To highlight the benefits of site-specific drug delivery.
Main Methods:
- Review of scientific literature on complement inhibitors.
- Analysis of targeting strategies for complement-mediated diseases.
- Evaluation of clinical evidence for targeted therapies.
Main Results:
- Targeted complement inhibitors concentrate drugs at specific sites.
- This targeted approach demonstrates increased efficacy.
- Site-specific delivery reduces undesirable side effects.
Conclusions:
- Targeted complement inhibition represents an advancement in treating complement-related disorders.
- The strategy offers a more effective and safer therapeutic profile.
- Further research into targeted drugs is warranted for autoimmune and inflammatory conditions.
Related Concept Videos
Complement System
Complementation Tests
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Microorganisms in Medicine and Therapeutics

